Additional file 1 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
posted on 2021-09-07, 03:26authored byGabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar
Additional file 1 Table 1. Patients with improvement, no change, or decline in HRQoL based on minimal clinically important differences defined by ≥ 10% of the instrument range. Table 1 describes the number and proportion of patients with improvement, no change, or decline in HRQoL based on the minimal clinically important difference threshold defined as ≥10% of the instrument range. Data are shown for the FACT-MM, FACT-G, FACT-MM TOI, and the MM domain at treatment cycle 2–6 and end of treatment.